IDYA
IDEAYA Biosciences, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Buy
+25/100
Last price
36.63
▼ 1.43 (3.76%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
38.57
Prev close
38.06
Day high
38.34
Day low
36.11
Volume
802.45K
Market cap
$3.53B
P/E (TTM)
—
52W range
26.05 – 42.68
Day trading desk
Gap from prior close
+1.34%
Prior close 38.06
VWAP
36.82
-0.52% from price
Relative volume
0.81×
Normal
Session range
12.15%
36.11 – 40.50
Position in range
12%
Near session low
ATR (14D)
1.66
4.54% of price
Prior day high
38.26
PDH
Prior day low
37.04
PDL
Bid / ask spread
—
Quote not published
Session volume
651.48K
Avg 799.74K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-3.25%
-5.2%
1M
-8.10%
-9.3%
3M
-3.50%
-8.0%
6M
+18.51%
+0.3%
YTD
+5.96%
-8.3%
1Y
+32.53%
+16.1%
3Y
+35.77%
-46.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on IDYA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
1
9.55K shares
Sell transactions
1
9.55K shares
Net transactions
+2
Buys less sells
Sell : buy shares
1.0 : 1
Mixed
Insider-held shares
2.12M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 7, 26 | RUIZ BRISENO ANDRES Officer |
SELL | 9.55K | $382.13K | Direct |
| Jul 7, 26 | RUIZ BRISENO ANDRES Officer |
CONVERSION | 9.55K | $122.81K | Direct |
| Mar 2, 26 | STEIN JEFFREY Director |
BUY | 50.00K | $1.65M | Direct |
| Nov 28, 25 | SNYDER DOUGLAS B General Counsel |
STOCK | 2.08K | $54.65K | Direct |
| Nov 28, 25 | RUIZ BRISENO ANDRES Officer |
STOCK | 1.94K | $60.49K | Direct |
| Feb 18, 25 | HATA YUJIRO S. Chief Executive Officer |
CONVERSION | 12.81K | $250.01K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
HATA YUJIRO S. |
Chief Executive Officer | 690.70K | Conversion of Exercise of derivative security |
RUIZ BRISENO ANDRES |
Officer | 26.47K | Sale |
SNYDER DOUGLAS B |
General Counsel | 2.08K | Stock Award(Grant) |
STEIN JEFFREY |
Director | 61.01K | Purchase |
Fundamentals
Market cap$3.53B
Enterprise value$2.73B
Revenue (TTM)$234.13M
Gross profit$-139.88M
EBITDA$-214.20M
Net income$-175.02M
EPS (TTM)$-1.86
Free cash flow$-70.85M
Total cash$828.96M
Total debt$29.31M
Book value / share$12.44
Shares outstanding96.49M
Float90.63M
Short % of float11.96%
Dividend yield0.00%
Beta (5Y)-0.04
Valuation & profitability ratios
Trailing P/E—
Forward P/E-9.14
PEG ratio—
Price / sales—
Price / book2.94
EV / revenue11.68
EV / EBITDA-12.77
Gross margin-59.75%
Operating margin-1380.73%
Profit margin-74.75%
Return on equity-16.22%
Return on assets-11.54%
Debt / equity2.44
Current ratio10.45
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $218.71M | $7.00M | $23.39M | $50.93M | +3,024.4% |
| Operating revenue | $218.71M | $7.00M | $23.39M | $50.93M | +3,024.4% |
| Research & development | $314.70M | $294.67M | $129.51M | $89.54M | +6.8% |
| Selling, general & admin | $63.32M | $39.30M | $28.31M | $23.90M | +61.1% |
| Total operating expense | $378.02M | $333.98M | $157.81M | $113.43M | +13.2% |
| Operating income | -$159.31M | -$326.98M | -$134.43M | -$62.50M | +51.3% |
| Net interest income | $45.62M | $52.50M | $21.47M | $3.85M | -13.1% |
| Pre-tax income | -$113.70M | -$274.48M | -$112.96M | -$58.66M | +58.6% |
| Net income | -$113.70M | -$274.48M | -$112.96M | -$58.66M | +58.6% |
| Net income to common | -$113.70M | -$274.48M | -$112.96M | -$58.66M | +58.6% |
| Basic EPS | -1.28 | -3.36 | -1.96 | -1.42 | +61.9% |
| Diluted EPS | -1.28 | -3.36 | -1.96 | -1.42 | +61.9% |
| EBIT | -$159.31M | -$326.98M | -$134.43M | -$62.50M | +51.3% |
| EBITDA | -$154.72M | -$323.14M | -$130.42M | -$58.99M | +52.1% |
| Basic shares | 88.49M | 81.68M | 57.52M | 41.44M | +8.3% |
| Diluted shares | 88.49M | 81.68M | 57.52M | 41.44M | +8.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $112.83M | $84.38M | $157.02M | $68.63M | — | +33.7% |
| Cash & short-term investments | $639.39M | $676.32M | $525.11M | $364.83M | — | -5.5% |
| Accounts receivable | — | $3.00K | $18.00K | $211.00K | $1.10M | — |
| Total current assets | $666.73M | $689.71M | $532.63M | $370.45M | — | -3.3% |
| Property, plant & equipment | $31.29M | $27.74M | $8.41M | $8.99M | — | +12.8% |
| Total assets | $1.11B | $1.12B | $649.32M | $387.97M | — | -1.3% |
| Total current liabilities | $58.81M | $46.07M | $27.10M | $31.72M | — | +27.7% |
| Total debt | $27.91M | $19.17M | $2.87M | $3.48M | — | +45.6% |
| Total liabilities | $86.39M | $64.94M | $28.23M | $38.51M | — | +33.0% |
| Retained earnings | -$736.54M | -$622.84M | -$348.36M | -$235.40M | — | -18.3% |
| Shareholder equity | $1.02B | $1.06B | $621.09M | $349.45M | — | -3.4% |
| Working capital | $607.91M | $643.64M | $505.53M | $338.74M | — | -5.6% |
| Net tangible assets | $1.02B | $1.06B | $621.09M | $349.45M | — | -3.4% |
| Shares issued | 87.80M | 86.50M | 65.04M | 48.19M | — | +1.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$113.70M | -$274.48M | -$112.96M | -$58.66M | +58.6% |
| Depreciation & amortisation | $4.59M | $3.83M | $4.01M | $3.52M | +19.8% |
| Stock-based compensation | $46.12M | $34.75M | $18.49M | $11.63M | +32.7% |
| Change in working capital | $1.87M | $11.55M | -$13.21M | -$42.97M | -83.8% |
| Operating cash flow | -$71.10M | -$247.58M | -$115.22M | -$87.17M | +71.3% |
| Capital expenditure | -$2.37M | -$3.86M | -$2.37M | -$3.44M | +38.6% |
| Investing cash flow | $69.98M | -$502.56M | -$158.46M | -$33.40M | +113.9% |
| Financing cash flow | $29.78M | $677.55M | $362.72M | $97.17M | -95.6% |
| Free cash flow | -$73.47M | -$251.44M | -$117.59M | -$90.62M | +70.8% |
| End cash position | $113.84M | $85.18M | $157.78M | $68.74M | +33.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $8.86M | $6.56M | $10.88M | $207.83M | $0 | +35.0% |
| Operating revenue | $8.86M | $6.56M | $10.88M | $207.83M | $0 | +35.0% |
| Research & development | $108.69M | $95.73M | $86.60M | $82.99M | $74.23M | +13.5% |
| Selling, general & admin | $22.46M | $19.38M | $18.85M | $16.39M | $14.58M | +15.9% |
| Total operating expense | $131.15M | $115.10M | $105.45M | $99.38M | $88.81M | +13.9% |
| Operating income | -$122.29M | -$108.54M | -$94.57M | $108.45M | -$88.81M | -12.7% |
| Net interest income | $9.84M | $10.01M | $11.30M | $10.79M | $11.31M | -1.7% |
| Pre-tax income | -$112.45M | -$98.54M | -$83.27M | $119.24M | -$77.49M | -14.1% |
| Net income | -$112.45M | -$98.54M | -$83.27M | $119.24M | -$77.49M | -14.1% |
| Net income to common | -$112.45M | -$98.54M | -$83.27M | $119.24M | -$77.49M | -14.1% |
| Basic EPS | -1.22 | -1.11 | -0.94 | 1.35 | -0.88 | -9.9% |
| Diluted EPS | -1.22 | -1.11 | -0.94 | 1.33 | -0.88 | -9.9% |
| EBIT | -$122.29M | -$108.54M | -$94.57M | $108.45M | -$88.81M | -12.7% |
| EBITDA | -$121.17M | -$107.40M | -$93.37M | $109.48M | -$87.57M | -12.8% |
| Basic shares | 92.06M | 88.70M | 88.58M | 88.53M | 88.47M | +3.8% |
| Diluted shares | 92.06M | 88.70M | 88.58M | 89.69M | 88.47M | +3.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $272.59M | $157.52M | $112.83M | $298.93M | $114.64M | +73.0% |
| Cash & short-term investments | $828.96M | $671.20M | $639.39M | $786.89M | $669.74M | +23.5% |
| Total current assets | $864.02M | $696.11M | $666.73M | $802.65M | $685.60M | +24.1% |
| Property, plant & equipment | $30.46M | $31.25M | $31.29M | $31.72M | $32.73M | -2.5% |
| Total assets | $1.31B | $1.03B | $1.11B | $1.19B | $1.04B | +27.1% |
| Total current liabilities | $82.68M | $64.83M | $58.81M | $64.51M | $55.34M | +27.5% |
| Total debt | $29.31M | $28.60M | $27.91M | $27.25M | $26.60M | +2.5% |
| Total liabilities | $110.79M | $93.08M | $86.39M | $93.10M | $81.62M | +19.0% |
| Retained earnings | -$947.53M | -$835.08M | -$736.54M | -$653.27M | -$772.51M | -13.5% |
| Shareholder equity | $1.20B | $937.27M | $1.02B | $1.09B | $959.65M | +27.9% |
| Working capital | $781.35M | $631.28M | $607.91M | $738.15M | $630.26M | +23.8% |
| Net tangible assets | $1.20B | $937.27M | $1.02B | $1.09B | $959.65M | +27.9% |
| Shares issued | 96.38M | 87.86M | 87.80M | 87.67M | 87.64M | +9.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$112.45M | -$98.54M | -$83.27M | $119.24M | -$77.49M | -14.1% |
| Depreciation & amortisation | $1.12M | $1.14M | $1.20M | $1.03M | $1.23M | -1.9% |
| Stock-based compensation | $16.66M | $14.54M | $11.79M | $12.22M | $11.87M | +14.6% |
| Change in working capital | $7.48M | $8.90M | -$18.69M | $11.71M | $4.61M | -16.0% |
| Operating cash flow | -$88.21M | -$75.17M | -$90.50M | $142.21M | -$62.47M | -17.3% |
| Capital expenditure | -$866.00K | -$967.00K | -$333.00K | -$42.00K | -$663.00K | +10.4% |
| Investing cash flow | -$155.93M | $118.95M | -$97.53M | $41.77M | $45.92M | -231.1% |
| Share buybacks | — | -$9.00K | — | — | — | — |
| Financing cash flow | $359.21M | $1.18M | $2.13M | $301.00K | $1.21M | +30,315.7% |
| Free cash flow | -$89.08M | -$76.14M | -$90.83M | $142.17M | -$63.14M | -17.0% |
| End cash position | $273.87M | $158.80M | $113.84M | $299.73M | $115.45M | +72.5% |
Options analytics
Put / call volume
0.35
Call-heavy session
Put / call open interest
0.21
Positioning, not flow
Max pain
25.00
-31.7% from spot
ATM implied vol
53.7%
Nearest strike to spot
Skew (10% OTM)
-55.4%
Calls bid over puts
Call volume
103
Contracts, this expiry
Put volume
36
Contracts, this expiry
Heaviest call OI
35.00
157 contracts
Heaviest put OI
25.00
20 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -1.05 | -1.22 | -16.2% |
| Mar 2026 | -0.98 | -1.11 | -13.5% |
| Dec 2025 | -0.95 | -0.94 | +0.6% |
| Sep 2025 | -0.55 | 1.33 | +341.8% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.16 | 12 | $6.84M | -96.7% |
| Next quarter | -1.12 | 12 | $20.83M | +91.5% |
| Current year | -4.58 | 12 | $41.10M | -81.2% |
| Next year | -4.01 | 12 | $119.76M | +191.4% |
Analyst targets & ownership
Mean target$52.75
High target$65.00
Low target$31.00
Implied upside44.01%
Analyst count12
ConsensusSTRONG BUY
Strong buy / Buy3 / 10
Hold1
Sell / Strong sell0 / 0
Held by insiders2.19%
Held by institutions107.70%
Institutions holding398
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
37.53
-2.39% from price
SMA 20
37.88
-3.31% from price
SMA 50
38.05
-3.74% from price
SMA 100
35.48
+3.25% from price
SMA 200
34.11
+7.39% from price
EMA 12
37.75
-2.96% from price
EMA 26
38.01
-3.63% from price
EMA 50
37.62
-2.62% from price
RSI (14)
42.4
Neutral
MACD (12,26,9)
-0.26
Hist -0.12
ATR (14)
1.66
4.54% of price
Realised vol 30D
36.9%
Annualised
Bollinger upper
39.36
20, 2σ
Bollinger lower
36.41
20, 2σ
50 / 200 cross
Golden
38.05 vs 34.11
Trend bias
Above 200
+7.39%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.98
Less volatile than market
Correlation to SPY
0.28
Largely independent
Realised vol 30D
36.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-27.1%
Peak to trough
Max drawdown 5Y
-69.2%
Peak to trough
ATR 14
1.66
4.54% of price
Beta (reported)
-0.04
5Y monthly, from filing
Short interest
Shares short
9.93M
Prior 10.40M
Change vs prior
-4.5%
Shorts covering
% of float
11.96%
Elevated
% of shares out
10.29%
Against total outstanding
Days to cover
13.9
Crowded exit
Float
90.63M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 9, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Sep 1, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Aug 5, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Aug 5, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Jul 7, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Jul 7, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Jun 12, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Jun 2, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| May 7, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| Apr 14, 26 | Goldman Sachs | MAINTAINED | Neutral | Neutral |
| Apr 14, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Apr 14, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-04
Corporate Changes & Voting Matters
8-K · 2026-06-23
Corporate Changes & Voting Matters
8-K · 2026-06-10
Corporate Changes & Voting Matters
8-K · 2026-06-03
Corporate Changes & Voting Matters
8-K · 2026-06-01
Proxy Statements
DEF 14A · 2026-04-29
Corporate Changes & Voting Matters
8-K · 2026-04-13
Corporate Changes & Voting Matters
8-K · 2026-04-09
Headlines
IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development
PR Newswire · 9d ago
Sagimet Biosciences (SGMT): Phase 3 Trial, FDA Path and Cash Runway Set Up Key Catalysts
Insider Monkey · 9d ago
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR Newswire · 12d ago
Can IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold?
Insider Monkey · 12d ago
Ideaya Biosciences, Servier Dose First Patient in Phase-3 Primary Uveal Melanoma Trial
MT Newswires · 28d ago
IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma
PR Newswire · 28d ago
IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences
PR Newswire · 36d ago
Sector Update: Healthcare Stocks Fall Premarket Monday
MT Newswires · 37d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.